دورية أكاديمية
Molecular profiling of non-small cell lung cancer.
| العنوان: | Molecular profiling of non-small cell lung cancer. |
|---|---|
| المؤلفون: | Forsythe ML; Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada., Alwithenani A; Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada.; Department of Laboratory Medicine, Faculty of Applied Medical Sciences, Umm Al-Qura University Makkah, Makkah, Saudi Arabia., Bethune D; Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Castonguay M; Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada., Drucker A; Division of Medical Oncology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Flowerdew G; Department of Epidemiology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., French D; Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Fris J; Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada., Greer W; Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada., Henteleff H; Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., MacNeil M; Division of Medical Oncology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Marignani P; Department of Biochemistry and Molecular Biology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Morzycki W; Division of Medical Oncology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Plourde M; Department of Surgery, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Snow S; Division of Medical Oncology, Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada., Xu Z; Department of Pathology, Faculty of Medicine, Dalhousie University Halifax, Halifax, Nova Scotia, Canada. |
| المصدر: | PloS one [PLoS One] 2020 Aug 05; Vol. 15 (8), pp. e0236580. Date of Electronic Publication: 2020 Aug 05 (Print Publication: 2020). |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: San Francisco, CA : Public Library of Science |
| مواضيع طبية MeSH: | Genetic Predisposition to Disease* , Prognosis*, Adenocarcinoma/*genetics , Carcinoma, Non-Small-Cell Lung/*genetics, Adenocarcinoma/classification ; Adenocarcinoma/epidemiology ; Adenocarcinoma/pathology ; Adult ; Aged ; Aged, 80 and over ; Anaplastic Lymphoma Kinase/genetics ; Carcinoma, Non-Small-Cell Lung/classification ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/pathology ; Class I Phosphatidylinositol 3-Kinases/genetics ; ErbB Receptors/genetics ; Female ; Humans ; Male ; Middle Aged ; Mutation/genetics ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; Receptor, ErbB-2/genetics |
| مستخلص: | Lung cancer is generally treated with conventional therapies, including chemotherapy and radiation. These methods, however, are not specific to cancer cells and instead attack every cell present, including normal cells. Personalized therapies provide more efficient treatment options as they target the individual's genetic makeup. The goal of this study was to identify the frequency of causal genetic mutations across a variety of lung cancer subtypes in the earlier stages. 833 samples of non-small cell lung cancer from 799 patients who received resection of their lung cancer, were selected for molecular analysis of six known mutations, including EGFR, KRAS, BRAF, PIK3CA, HER2 and ALK. A SNaPshot assay was used for point mutations and fragment analysis searched for insertions and deletions. ALK was evaluated by IHC +/- FISH. Statistical analysis was performed to determine correlations between molecular and clinical/pathological patient data. None of the tested variants were identified in most (66.15%) of cases. The observed frequencies among the total samples vs. only the adenocarcinoma cases were notable different, with the highest frequency being the KRAS mutation (24.49% vs. 35.55%), followed by EGFR (6.96% vs. 10.23%), PIK3CA (1.20% vs. 0.9%), BRAF (1.08% vs. 1.62%), ALK (0.12% vs. 0.18%), while the lowest was the HER2 mutation (0% for both). The statistical analysis yielded correlations between presence of a mutation with gender, cancer type, vascular invasion and smoking history. The outcome of this study will provide data that helps stratify patient prognosis and supports development of more precise treatments, resulting in improved outcomes for future lung cancer patients. Competing Interests: The study was partially supported by Roche Canada, Pfizer Canada and Boehringer Ingelheim Canada. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. The funding provided by the pharmaceutical companies were helping us for validation of the tests and not related to employment, consultancy, patents, products in development, marketed products, and any commercial purposes. This does not alter our adherence to PLOS ONE policies on sharing data and materials. |
| References: | Chin J Cancer. 2013 Feb;32(2):63-70. (PMID: 22776234) Cancer. 2013 Jan 15;119(2):356-62. (PMID: 22810899) Clin Cancer Res. 2006 Oct 1;12(19):5764-9. (PMID: 17020982) Oncogene. 2009 Aug;28 Suppl 1:S24-31. (PMID: 19680293) Clin Lung Cancer. 2013 Sep;14(5):581-91. (PMID: 23827517) N Engl J Med. 2011 Mar 10;364(10):947-55. (PMID: 21388312) Lancet Oncol. 2016 Jul;17(7):984-993. (PMID: 27283860) J Clin Oncol. 2018 Sep 10;36(26):2693-2701. (PMID: 29768119) J Natl Cancer Inst. 2005 Mar 2;97(5):339-46. (PMID: 15741570) J Thorac Oncol. 2015 Sep;10(9):1243-1260. (PMID: 26291008) Transl Lung Cancer Res. 2016 Jun;5(3):288-300. (PMID: 27413711) Cancer Sci. 2006 Dec;97(12):1351-8. (PMID: 17052259) Ann Oncol. 2011 Dec;22(12):2616-2624. (PMID: 22071650) Mod Pathol. 2004 Mar;17(3):328-48. (PMID: 14976539) Lancet Oncol. 2016 Apr;17(4):452-463. (PMID: 26973324) J Mol Diagn. 2010 Jul;12(4):453-60. (PMID: 20431033) J Clin Oncol. 2012 Mar 10;30(8):863-70. (PMID: 22215748) Clin Cancer Res. 2009 Aug 15;15(16):5267-73. (PMID: 19671843) N Engl J Med. 2018 Jan 11;378(2):113-125. (PMID: 29151359) J Clin Oncol. 2018 Mar 20;36(9):841-849. (PMID: 28841389) Adv Exp Med Biol. 2016;893:1-19. (PMID: 26667336) Clin Cancer Res. 2011 Apr 15;17(8):2081-6. (PMID: 21288922) Nat Genet. 2000 Apr;24(4):381-6. (PMID: 10742102) Ann Transl Med. 2017 Sep;5(18):373. (PMID: 29057233) Laryngoscope. 2009 Dec;119(12):2411-6. (PMID: 19718752) Transl Lung Cancer Res. 2015 Feb;4(1):67-81. (PMID: 25806347) J Natl Cancer Inst. 2013 May 1;105(9):595-605. (PMID: 23594426) N Engl J Med. 2017 Aug 31;377(9):829-838. (PMID: 28586279) N Engl J Med. 2005 Feb 24;352(8):786-92. (PMID: 15728811) Clin Cancer Res. 2006 Nov 1;12(21):6494-501. (PMID: 17085664) N Engl J Med. 2017 Feb 16;376(7):629-640. (PMID: 27959700) J Natl Cancer Inst. 1999 Dec 1;91(23):2032-8. (PMID: 10580029) Lancet. 2011 Jan 8;377(9760):127-38. (PMID: 21183212) J Clin Oncol. 2016 Dec;34(34):4079-4085. (PMID: 27863201) N Engl J Med. 2013 Jun 20;368(25):2385-94. (PMID: 23724913) Lung Cancer. 2006 Nov;54(2):209-15. (PMID: 16930767) Nature. 2012 Sep 27;489(7417):519-25. (PMID: 22960745) |
| المشرفين على المادة: | 0 (KRAS protein, human) EC 2.7.1.137 (Class I Phosphatidylinositol 3-Kinases) EC 2.7.1.137 (PIK3CA protein, human) EC 2.7.10.1 (ALK protein, human) EC 2.7.10.1 (Anaplastic Lymphoma Kinase) EC 2.7.10.1 (EGFR protein, human) EC 2.7.10.1 (ERBB2 protein, human) EC 2.7.10.1 (ErbB Receptors) EC 2.7.10.1 (Receptor, ErbB-2) EC 2.7.11.1 (BRAF protein, human) EC 2.7.11.1 (Proto-Oncogene Proteins B-raf) EC 3.6.5.2 (Proto-Oncogene Proteins p21(ras)) |
| تواريخ الأحداث: | Date Created: 20200807 Date Completed: 20201002 Latest Revision: 20201002 |
| رمز التحديث: | 20221213 |
| مُعرف محوري في PubMed: | PMC7406040 |
| DOI: | 10.1371/journal.pone.0236580 |
| PMID: | 32756609 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 1932-6203 |
|---|---|
| DOI: | 10.1371/journal.pone.0236580 |